Abstract: The present disclosure is a method for controlling a battery power interface converter with an ultra-wideband EIS measurement function. According to the present disclosure, a discrete pulse control method based on discrete pulse modulation is adopted, which, by generating two discrete duty ratio signals and according to a relationship between a battery charging current and a reference current, selects an appropriate duty ratio signal from the two discrete duty ratio signals to generate a control pulse signal to act on the battery power interface converter. The method of the present disclosure achieves accurate tracking of the output current of the power interface converter to DC charging or ultra-wideband hybrid reference current. A battery charging control system can achieve a normal constant-current charging function while operating in a constant-current charging mode and the ultra-wideband EIS of a battery accurate measurement function in an EIS measurement mode.

Abstract: Provided is a method for preparing oxidized glutathione and a new crystal form and impurity thereof, including the following steps: using dimethyl sulfoxide (DMSO) as an oxidizing agent to oxidize reduced glutathione to crude oxidized glutathione; and recrystallizing and refining in purified water to obtain high-purity heptahydrate crystals of oxidized glutathione.

Abstract: A composition and method for generating patient- or person-specific proliferative and substantially pure cardiac myocyte cell lines from pluripotent stem cells (iPSCs) is described herein. The patient-specific cardiac myocyte cell lines of the present invention find applications in research, drug screening and autologous cell-based therapy. The method of the present invention is simple and reproducible and generates cardiac myocyte cells having high purities and proliferating capacities.

Abstract: A composition and method for generating patient- or person-specific proliferative and substantially pure cardiac myocyte cell lines from pluripotent stem cells (iPSCs) is described herein. The patient-specific cardiac myocyte cell lines of the present invention find applications in research, drug screening and autologous cell-based therapy. The method of the present invention is simple and reproducible and generates cardiac myocyte cells having high purities and proliferating capacities.

Abstract: Novel therapies for the treatment of Fabry disease by using androgen/androgen receptor (AR) pathway-related molecules as biomarkers and use of approaches targeting androgen/AR pathway are presented herein. The involvement of aberrant androgen/AR pathway in Fabry disease has never been previously described. The present invention describes, (i) use of approaches that target androgen/AR pathway as therapeutic treatments for Fabry disease and (2) use of the levels of androgen/AR pathway-related molecules in body fluids or tissues as biomarkers for evaluation of disease progression and efficacy of treatments in Fabry patients.